Abstract
Intracranial Stereotactic Radiosurgery (SRS) was a new treatment method for brain tumors introduced in the twentieth century to deliver tight spatial/temporal distribution using a high precision technique. The clinical experience from intracranial SRS, together with the technical developments in conventional RT, initiated the development of Stereotactic Body Radiation Therapy (SBRT) for extracranial tumors characterized by a very high dose per fraction, delivered in a short time. This was started at the Swedish Karolinska University hospital in 1991 with tumors in the liver and lungs by Bromgren and Lax [1–3]. In parallel this method was developed in Japan and clinically introduced in 1994 for lung tumors [4–6]. During the last 5 years of the nineties, SBRT was introduced in several centers in Europe, Japan and USA. Wulf and Herfarth in Germany reported theis clinical results on lung cancer in 2001, followed by Timmerman in USA in 2003. The early reports had already shown very promising results with regard to local control and toxicity for the hypofractionation schedules which were adopted with 10–15 Gy/fraction given in 3–5 fractions during a short time. However, due to the new aspects introduced in SBRT, clinical experience was initially accumulated at a very slow rate and it was only during the last decade that outcome data from several centers was available to confirm the initial promising results. In this session, the historical development of SBRT was reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lax I, Blomgren H, Näslund I, et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33:677–83.
Lax I, Blomgren H, Larson D, et al. Extracranial stereotactic radiosurgery of localized targets. J Radiosurg. 1998;1:135–48.
Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol. 1995;34:861–70.
Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients. Cancer. 1998;82:1062–70.
Uematsu M, Shioda M, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–70.
Arimoto T, Usubuchi H, Matsuzawa T, et al. Small volume multiple non-coplanar arc radiotherapy for tumors of the lung, head & neck and the abdominopelvic region. Tokyo: Elsevier; 1998.
Bibliography
3rd Acta Oncologica symposium on stereotactic body radiotherapy. Copenhagen: Acta Oncol. 2006;45:771–994.
Bauman P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–6.
Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–95.
Blomgren H, Lax I, Göranson H, et al. Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurg. 1998;1:63–74.
Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol. 1995;34:861–70.
Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:967–71.
Dawson L, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006;45:856–64.
Fakiris A, McGarry RC, Yiannoustsons CT, et al. Stereotactic body radiation therapy for early-stage non-small cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75:677–82.
Guckenberger M, Meyer J, Wilbert J, et al. Intra-fractional uncertainties in cone-beam CT based image-guided radiotherapy of pulmonary tumors. Radiother Oncol. 2007;83:57–64.
Haedinger U, Wulf J. Quality assurance in stereotactic body radiation therapy. In: Kavanagh BD, Timmerman R, editors. Stereotactic body radiation therapy. Philadelphia: Lippincott, Williams & Wilkins; 2005.
Hara R, Itami J, Kondo T, et al. Clinical outcomes of single-fraction radiation therapy for lung tumors. Cancer. 2006;1006:1347–52.
Herfarth KK, Debus J, Lohr F, et al. Stereotactic single dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164–70.
Herfarth KK, Debus J. Stereotaktische Strahlentherapie von Lebermetastasen. Der Chirurg. 2005;76:564–9.
Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48–53.
Joyner M, Salter BJ, Papanikolaou N, et al. Stereotactic body radiation therapy for centrally located lung tumors. Acta Oncol. 2006;45:802–7.
Kavanagh B, Schefter T, Cardenes H, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45:848–55.
Kavanagh BD, McGarry R, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol. 2006;16:77–84.
Koong AC, Christofferson E, Le Q, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63.
Koong AC, Le Q, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017–21.
Laagerward F, Van Sornsen de Koste J, Nijssen-Visser M, et al. Multiple “slow” CT scans for incorporating lung tumor mobility in radiotherapy planning. Int J Radiat Oncol Biol Phys. 2001;51:932–7.
Lee S, Choi E, Park H, et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer. 2003;40:309–15.
Lehnert T, Golling M. Indikationen und Ergebnisse der Lebermetastasenresektion. Radiologe. 2001;41:40–8.
Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry. 1983;46:797–803.
Leksell L. The stereotactic method and radiosurgery of the brain. Acta Chir Scand. 1951;102:316–19.
Loo BW, Chang JY, Dawson LA. Stereotactic ablative radiosurgery: what’s in a name. Pract Radiat Oncol. 2011;1:38–9.
McGarry R, Papiez L, Williams M, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–15.
Mendez-Romero A, Wunderink W, Hussain S, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single-institution phase I–II study. Acta Oncol. 2006;45:831–7.
Nagata Y, Matsuo Y, Takayama K, et al. Survey of SBRT in Japan. Int J Radiat Oncol Biol Phys. 2009;75:343–7.
Nagata Y, Negoro Y, Aoki T, et al. Clinical outcomes of 3D conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2002;52:1041–6.
Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–31.
Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiation therapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72:398–403.
Onimaru R, Shirato H, Shimizu S, et al. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003;56:126–35.
Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma. Cancer. 2004;101:1623–31.
Pannetieri V, Wennberg B, Gagliardi G, et al. SBRT of lung tumors: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems. Phys Med Biol. 2007;52:4265–81.
Potter L, Steinberg M, Rose C, et al. American Society of Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004;60:1026–32.
Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579–84.
Schefter T, Kavanagh B, Timmerman R, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62:1371–8.
Shirato H, Shimizu S, Tadashi S, et al. Real time tumor tracking radiotherapy. Lancet. 1999;353:1331–2.
Takayama K, Nagata Y, Negoro Y, et al. Treatment planning of stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2005;61:1565–71.
Timmerman R, Galvin J, Michalski J, et al. Accreditation and quality assurance for Radiation Oncology Group: multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol. 2006;45:779–86.
Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.
Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–55.
Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2007;27(Suppl.3):S101–12, Appendix.
Timmermann R, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.
Wersaell P, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77:88–95.
Wulf J, Baier K, Mueller G, et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005;77:83–7.
Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838–47.
Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177:645–55.
Wulf J, Haedinger U, Oppitz U, et al. Stereotactic radiotherapy of primary lung cancer and pulmonary metastases: a non-invasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60:186–96.
Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–25.
Yaes RJ, Patel P, Maruyama Y. On using the linear-quadratic model in daily clinical practice. Int J Radiat Oncol Biol Phys. 1991;20:1353–62.
Zimmermann F, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer. 2005;48:107–14.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Japan
About this chapter
Cite this chapter
Nagata, Y. (2015). Introduction and History of Stereotactic Body Radiation Therapy (SBRT). In: Nagata, Y. (eds) Stereotactic Body Radiation Therapy. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54883-6_1
Download citation
DOI: https://doi.org/10.1007/978-4-431-54883-6_1
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54882-9
Online ISBN: 978-4-431-54883-6
eBook Packages: MedicineMedicine (R0)